Delivery Order SPE2DB24D6039-SPE2DB25FLEKK
- Not listed
- The Defense Logistics Agency awarded a $26,328.21 delivery order to AmerisourceBergen Drug Corp on August 13, 2025, for the supply of Dupixent 300 mg/2 ml pen injectors (2 ml units). This is a firm fixed price, non-set-aside contract with an ultimate completion date of August 14, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. Dupixent (dupilumab) is a biologic medication used to treat moderate-to-severe atopic dermatitis,...
- The Defense Logistics Agency awarded a $40,995.34 delivery order to AmerisourceBergen Drug Corp on April 25, 2025, for the supply of Dupixent 300 mg/2 ml pen injectors. This competitively awarded, non-set-aside contract specifies firm fixed pricing with an ultimate completion date of April 28, 2025, and will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. Dupixent (dupilumab) is a biologic medication used to treat moderate-to-severe atopic dermatitis,...
- The Defense Logistics Agency awarded a delivery order valued at $17,474.93 to AmerisourceBergen Drug Corp on July 14, 2025, for the supply of Dupixent 300 mg/2 mL pen injectors. This is a firm fixed price, non-set-aside contract with an ultimate completion date of July 15, 2025, with performance taking place at AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. Dupixent (dupilumab) is a biologic medication used to treat various allergic and inflammatory conditions, including...
- The Defense Logistics Agency awarded a $17,929.57 delivery order to AmerisourceBergen Drug Corp on September 17, 2025, for Dupixent 200 mg/1.14 mL pen injectors. This is a firm fixed-price, non-set-aside delivery order with a completion date of September 18, 2025, and will be performed at the contractor's facility in Conshohocken, Pennsylvania. Dupixent (dupilumab) is a monoclonal antibody used to treat conditions including moderate-to-severe eczema, asthma, and chronic rhinosinusitis, making...
- The Defense Logistics Agency awarded a $21,976.95 delivery order to AmerisourceBergen Drug Corp on July 28, 2025, for the supply of Dupixent 300 mg/2 ml pen injectors (2 ml units). This is a firm fixed price, non-set-aside contract with a completion date of July 29, 2025, and will be performed at the vendor's corporate office location in Conshohocken, Pennsylvania. Dupixent (dupilumab) is a biologic medication used to treat moderate-to-severe eczema, asthma, chronic rhinosinusitis with nasal...
- The Defense Logistics Agency awarded a $27,552.50 delivery order to AmerisourceBergen Drug Corp on June 5, 2025, for the supply of Dupixent 300 mg/2 ml pen injectors. This is a firm fixed-price, non-set-aside delivery order with an ultimate completion date of June 6, 2025, and will be performed at the vendor's corporate office location in Conshohocken, Pennsylvania. Dupixent (dupilumab) is a biologic medication primarily indicated for moderate-to-severe atopic dermatitis, eosinophilic...
- The Defense Logistics Agency awarded a delivery order valued at $9,380.82 to AmerisourceBergen Drug Corp for Dupixent 300 mg/2 mL pen injectors on August 8, 2025, with an ultimate completion date of August 11, 2025. This firm fixed-price delivery order represents a non-competitive, non-set-aside award and is being performed at the contractor's corporate office location in Conshohocken, Pennsylvania. Dupixent (dupilumab) is a biologic medication used to treat moderate-to-severe atopic dermatitis,...
- The Defense Logistics Agency awarded a delivery order valued at $14,005.70 to AmerisourceBergen Drug Corp for the supply of Dupixent 300 mg/2 mL pen injectors on August 21, 2025, with completion scheduled for August 22, 2025. This competitively awarded, firm fixed-price delivery order was issued without set-aside designation and will be performed at the vendor's corporate office location in Conshohocken, Pennsylvania. Dupixent (dupilumab) is a biologic medication used to treat conditions such as...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $35,016.86 for Dupixent 300 mg/2 ml pen injectors on August 15, 2025, with an ultimate completion date of August 18, 2025. This competitively awarded, firm fixed-price delivery order carries no set-aside designation and will be performed at the awardee's location in Conshohocken, Pennsylvania. Dupixent (dupilumab) is a biologic medication used to treat moderate-to-severe atopic dermatitis, eosinophilic...
- The Defense Logistics Agency awarded a $56,394.80 delivery order to AmerisourceBergen Drug Corp on August 18, 2025, for the supply of Dupixent 300 mg/2 ml pen auto-injectors. This competitively awarded, firm fixed-price delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. The product will be delivered to AmerisourceBergen's distribution...
- SPE2DB24D6039Indefinite Delivery Contract
- SPE2DB24D6039-SPE2DB25FLEKKDelivery Order
The Defense Logistics Agency awarded a $14,369.52 delivery order to AmerisourceBergen Drug Corp on July 24, 2025, for the supply of Dupixent 200 mg/1.14 mL pen injectors. This competitively awarded, non-set-aside contract carries a firm fixed price structure with an ultimate completion date of July 25, 2025, and will be performed at the contractor's corporate office in Conshohocken, Pennsylvania. Dupixent (dupilumab) is a biologic immunosuppressant medication used to treat moderate-to-severe atopic dermatitis, eosinophilic esophagitis, and asthma, making this a specialty pharmaceutical supply order for federal healthcare programs. This delivery order derives from AmerisourceBergen Drug Corp's comprehensive Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026. As a major pharmaceutical distributor and critical federal vendor, AmerisourceBergen maintains an extensive portfolio of medical product deliveries supporting military and veteran healthcare systems. The parent IDC serves as a global pharmaceutical support vehicle enabling the company to supply a vast range of specialty medications, brand-name and generic drugs, and medical commodities across multiple therapeutic domains to support defense healthcare programs worldwide, including the Defense Health Agency and U.S. Coast Guard.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $14.4k | 7/24/25 |